Vanoglipel
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Vanoglipel ( ), also known by its developmental code name DA-1241, is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes.
Vanoglipel ( ), also known by its developmental code name DA-1241, is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes. ==References==
Text derived from https://en.wikipedia.org/w/index.php?oldid=1339297873 under CC BY-SA 4.0; modifications have been made.